Evidence map›Paper›PMID 41486437›Full record

ReviewInfection & chemotherapy2025

COVID-19 Vaccination Recommendations for 2025-2026 in Korea.

Wan Beom Park, Young Hoon Hwang, Ki Tae Kwon, Ji Yun Noh, Sun Hee Park, Joon Young Song, Eun Ju Choo, Min Joo Choi, Jun Yong Choi, Jung Yeon Heo and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infection & chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. COVID-19 Vaccination Strategy and Evidence in Korea.Journal of Korean medical science · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wan Beom ParkDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. wbpark1@snu.ac.kr.ORCID https://orcid.org/0000-0003-0022-9625
Young Hoon HwangDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-2653-0221
Ki Tae KwonDivision of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID https://orcid.org/0000-0003-4666-0672
Ji Yun NohDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-8541-5704
Sun Hee ParkDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-5648-9237
Joon Young SongDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0148-7194
Eun Ju ChooDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Bucheon, Korea.ORCID https://orcid.org/0000-0003-2842-7041
Min Joo ChoiDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2739-0948
Jun Yong ChoiDivision of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2775-3315
Jung Yeon HeoDepartment of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea.ORCID https://orcid.org/0000-0002-6548-1939
Won Suk ChoiDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-5874-4764
Committee of Adult Immunization in the Korean Society of Infectious Diseases

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Korean Society of Infectious Diseases has regularly updated its adult immunization guidelines, including the coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023 and the 2024-2025 seasonal update. This article provides a comprehensive update as of September 2025, reflecting the latest evidence and international guidance. Focusing on the 2025-2026 season, it reviews vaccines currently authorized in Korea and their effectiveness against predominant JN.1 sublineage variants, including LP.8.1, NB.1.8.1, and XFG. The updated recommendations prioritize vaccination with LP.8.1-adapted vaccines for high-risk groups-adults aged 65 years and older, individuals aged 6 months and older at increased risk for severe disease, and residents of facilities vulnerable to infection-while vaccination remains available for all individuals aged 6 months and older. A single-dose strategy is generally recommended, although older adults and immunocompromised individuals may consider an additional dose at 6-month intervals in consultation with healthcare professionals. These updates aim to refine Korea's COVID-19 vaccination strategy and sustain protection in high-risk populations, with recommendations remaining subject to revision as new evidence and epidemiological conditions evolve.

Indexed as

COVID-19SARS-CoV-2Vaccination

Identifiers

PMID41486437
PMCPMC12802021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.